SHANGHAI, July 3 /PRNewswire-Asia/ -- Sundia MediTech, a leading integrated pharmaceutical and biotech R&D outsourcing company in Shanghai, China announced today that Dr. Chen Chen has been appointed Senior Vice President of Chemistry Services.
Prior to joining Sundia, Dr. Chen worked at Neurocrine Biosciences, a drug discovery and development company in San Diego, USA for 15 years, from a staff scientist to Senior Director of Medicinal Chemistry of Neurocrine. In his research and management positions at Neurocrine, Dr. Chen achieved many outstanding scientific and industrial accomplishments, including development of two small molecule antagonists, NBI-42902 and elagolix (aka NBI-56418), of the gonadotropin-releasing hormone receptor into clinical studies. Elagolix, the most advanced in this class, is currently finishing Phase II trials by Neurocrine for the treatment of endometriosis. Dr. Chen designed, synthesized and developed NBI-30775 (R121919), a small molecule antagonist of the corticotrophin-releasing factor receptor as the first-in-class compound advanced into clinical trials for depression/anxiety. Dr. Chen also discovered NBI-31772, the first small molecule inhibitor for the insulin-like growth factor-I/IGF-binding protein. In addition, Dr. Chen identified the first selective antagonist of the melanocortin-5 receptor, and discovered numerous agonists and antagonists for the melanocortin-4 receptor for eating disorders.
Dr. Chen has extensive experience in CNS drug research and GPCRs as drug targets. His knowledge also includes neuropathic pain and metabolic disorders. His research interests extend to clinic and preclinic pharmacokinetics of small molecules and the relationship with their chemical properties.
"It is an honor for Sundia to have world class leading scientists as Dr.
Chen in our senior management team. As our clients worldwide are bringing
more and more high
'/>"/>
| SOURCE Sundia MediTech Company Copyright©2009 PR Newswire. All rights reserved |